Avecho Biotechnology Limited

CHIA:AVE Stock Report

Market Cap: AU$9.5m

Avecho Biotechnology Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of AVE?
Owner TypeNumber of SharesOwnership Percentage
Institutions151,646,4704.78%
Private Companies242,474,9507.65%
Individual Insiders797,958,87525.2%
General Public1,977,216,71862.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 22 shareholders own 37.61% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.89%
Chunyan Niu
250,000,000AU$750.0k0%no data
5.51%
Mark Kerr
174,566,594AU$523.7k0%no data
5.51%
Linda Kerr
174,566,594AU$523.7k0%no data
3.19%
Melbourne Securities Corporation Ltd
101,012,290AU$303.0k0%4.61%
2.7%
Rosscope Pty Ltd
85,513,129AU$256.5k0%no data
1.58%
Wayne Kent
50,000,000AU$150.0k0%no data
1.57%
Hirsch Financial Pty Ltd, Asset Management Arm
49,878,323AU$149.6k0%24.47%
1.41%
Brandon Batagol
44,532,406AU$133.6k0%no data
1.21%
180 Markets Pty Ltd
38,333,333AU$115.0k0%no data
1.07%
1215 Capital Pty Ltd
33,801,008AU$101.4k0%no data
1.05%
Hunt Prosperity Pty Ltd
33,333,333AU$100.0k0%no data
0.98%
Servbond Pty Limited
31,000,000AU$93.0k0%no data
0.73%
David Segal
23,000,000AU$69.0k0%no data
0.71%
Raymond Carroll
22,500,000AU$67.5k0%no data
0.69%
Tony Amato
22,000,000AU$66.0k0%no data
0.65%
FF Okram Pty Ltd
20,494,147AU$61.5k0%no data
0.35%
Roksan Libinaki
11,100,441AU$33.3k0%no data
0.34%
Paul Gavin
10,859,508AU$32.6k0%no data
0.31%
Gregory Collier
9,833,333AU$29.5k-15.7%no data
0.11%
Ross Murdoch
3,333,333AU$10.0k0%no data
0.053%
Matthew McNamara
1,666,666AU$5.0k0%no data
0.024%
Australian Super Pty Ltd
755,857AU$2.3k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 18:51
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Avecho Biotechnology Limited is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dennis HulmeAPP Securities Pty Ltd.
Scott PowerMorgans Financial Limited
David StantonNomura Securities Co. Ltd.